

Daniel C Baumgart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12188443/publications.pdf>

Version: 2024-02-01

53
papers

10,735
citations

126907

33
h-index

168389

53
g-index

58
all docs

58
docs citations

58
times ranked

12529
citing authors

#	ARTICLE	IF	CITATIONS
1	Artificial intelligence enabled automated diagnosis and grading of ulcerative colitis endoscopy images. <i>Scientific Reports</i> , 2022, 12, 2748.	3.3	38
2	Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. <i>New England Journal of Medicine</i> , 2021, 385, 1302-1315.	27.0	137
3	Digital advantage in the COVID-19 response: perspective from Canada's largest integrated digitalized healthcare system. <i>Npj Digital Medicine</i> , 2020, 3, 114.	10.9	52
4	Darvadstrocel for the treatment of perianal fistulas in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 405-410.	3.0	15
5	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 144-164K.	1.3	958
6	Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. <i>Frontiers in Pharmacology</i> , 2019, 10, 279.	3.5	89
7	Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 442-448.	1.5	12
8	Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1334-1342.e4.	1.3	331
9	Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating \hat{I}^{27+} T Cells in Crohn's Disease: Report of the TOSCA Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 188-196.	1.3	24
10	Immunosuppression following liver transplantation and the course of inflammatory bowel disease – a case control study. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, 117-127.	0.5	3
11	Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach. <i>Digestive Diseases</i> , 2018, 36, 346-353.	1.9	1
12	Immunobiology of Human Dendritic Cells in Inflammatory Bowel Disease. , 2017, , 93-100.		0
13	Use of Intestinal Ultrasound to Monitor Crohn's Disease Activity. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 535-542.e2.	4.4	165
14	5. <i>Mikrobiom.</i> , 2017, , .		0
15	Tablet computer enhanced training improves internal medicine exam performance. <i>PLoS ONE</i> , 2017, 12, e0172827.	2.5	31
16	Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. <i>Lancet, The</i> , 2016, 388, 1281-1290.	13.7	771
17	Association Between Response to Etrolizumab and Expression of Integrin $\hat{I}\pm E$ and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 477-487.e9.	1.3	133
18	The Expenditures for Academic Inpatient Care of Inflammatory Bowel Disease Patients Are Almost Double Compared with Average Academic Gastroenterology and Hepatology Cases and Not Fully Recovered by Diagnosis-Related Group (DRG) Proceeds. <i>PLoS ONE</i> , 2016, 11, e0147364.	2.5	11

#	ARTICLE	IF	CITATIONS
19	Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab. Drug Design, Development and Therapy, 2015, 9, 147.	4.3	7
20	US-based Real-time Elastography for the Detection of Fibrotic Gut Tissue in Patients with Stricturing Crohn Disease. Radiology, 2015, 275, 889-899.	7.3	111
21	Ferric Maltol Is Effective in Correcting Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 579-588.	1.9	108
22	Glucocorticoids regulate barrier function and claudin expression in intestinal epithelial cells via MKP-1. American Journal of Physiology - Renal Physiology, 2014, 306, G218-G228.	3.4	67
23	Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet, The, 2014, 384, 309-318.	13.7	421
24	A randomised phase I study of etrolizumab (rhuMAB \hat{I}^{27}) in moderate to severe ulcerative colitis. Gut, 2013, 62, 1122-1130.	12.1	134
25	Acetylsalicylic Acid Reduces the Severity of Dextran Sodium Sulfate-Induced Colitis and Increases the Formation of Anti-Inflammatory Lipid Mediators. BioMed Research International, 2013, 2013, 1-10.	1.9	23
26	Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF- \hat{I}^{\pm} on tight junction proteins and signaling pathways in intestinal epithelial cells. American Journal of Physiology - Renal Physiology, 2013, 304, G970-G979.	3.4	103
27	Conventional Medical Management of Ulcerative Colitis: Tacrolimus. , 2012, , 487-494.		1
28	Crohn's disease. Lancet, The, 2012, 380, 1590-1605.	13.7	1,722
29	Toxic megacolon. Inflammatory Bowel Diseases, 2012, 18, 584-591.	1.9	107
30	Targeting leukocyte migration and adhesion in Crohnâ€™s disease and ulcerative colitis. Inflammopharmacology, 2012, 20, 1-18.	3.9	172
31	Immunobiology of Dendritic Cells in Inflammatory Bowel Disease. , 2012, , 141-149.		0
32	A Phase I Study of rHuMab Beta7 in Moderate to Severe Ulcerative Colitis (UC). Gastroenterology, 2011, 140, S-125.	1.3	7
33	Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients. Inflammatory Bowel Diseases, 2011, 17, 2512-2520.	1.9	53
34	Smartphones in Clinical Practice, Medical Education, and Research. Archives of Internal Medicine, 2011, 171, 1294.	3.8	62
35	Extended colonic release low-molecular weight heparin (LMWH) not ready for use in ulcerative colitis. Evidence-Based Medicine, 2011, 16, 71-72.	0.6	3
36	Endoscopic Surveillance in Crohnâ€™s Disease and Ulcerative Colitis: Who Needs What and When?. Digestive Diseases, 2011, 29, 32-35.	1.9	8

#	ARTICLE	IF	CITATIONS
37	Anti-inflammatory effects of <i>Saccharomyces boulardii</i> mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G1083-G1092.	3.4	51
38	Veto on vedolizumab (MLN0002) for Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 537-538.	1.9	4
39	Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 620-629.	1.9	46
40	Impact of pain on health-related quality of life in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2010, 16, 3168.	3.3	128
41	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 63-101.	1.3	695
42	How many lives does an ulcerative colitis patient have?. <i>Lancet, The</i> , 2010, 376, 928.	13.7	2
43	Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. <i>Gut</i> , 2010, 59, 1485-1492.	12.1	71
44	Transient Cytokine-Induced Liver Injury Following Administration of the Humanized Anti-CD3 Antibody Visilizumab (HuM291) in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2009, 104, 868-876.	0.4	26
45	The Diagnosis and Treatment of Crohn's Disease and Ulcerative Colitis. <i>Deutsches Arzteblatt International</i> , 2009, 106, 123-33.	0.9	64
46	Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. <i>The Cochrane Library</i> , 2008, , CD007216.	2.8	42
47	Inflammatory bowel disease: cause and immunobiology. <i>Lancet, The</i> , 2007, 369, 1627-1640.	13.7	1,656
48	Inflammatory bowel disease: clinical aspects and established and evolving therapies. <i>Lancet, The</i> , 2007, 369, 1641-1657.	13.7	1,593
49	The c.1-260C>T Promoter Variant of CD14 but Not the c.896A>G (p.D299G) Variant of Toll-Like Receptor 4 (TLR4) Genes Is Associated with Inflammatory Bowel Disease. <i>Digestion</i> , 2007, 76, 196-202.	2.3	33
50	Recognition and appropriate management of dysplasia-associated lesions or masses in inflammatory bowel disease—experience does matter. <i>Gastrointestinal Endoscopy</i> , 2007, 66, 530-532.	1.0	2
51	Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon-1a. <i>World Journal of Gastroenterology</i> , 2007, 13, 3638.	3.3	33
52	Personal digital assistants in health care: experienced clinicians in the palm of your hand?. <i>Lancet, The</i> , 2005, 366, 1210-1222.	13.7	127
53	Intestinal barrier function. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2002, 5, 685-694.	2.5	204